Fig 1.

rLm.SIVgag immunogenicity in mice. (A) Groups of C57BL/6 mice (n = 8/group) received oral escalating doses of rLm.SIVgag (0 or 10⁸ to 10¹¹ CFU) (Lm Prime) and were then boosted i.m. with rAd5.SIVgag (0 or 10⁷ vp; n = 4/group) (Ad5 Boost) 4 weeks later. The inset shows the AL11-specific CD8⁺ T lymphocyte responses at weeks 0 to 4 in a smaller scale. (B) C57BL/6 mice (n = 4) received orally two consecutive doses of 10¹⁰ CFU rLm.SIVgag at weeks 0 and 4. Animals were bled at the indicated time points, and AL11-specific CD8⁺ T lymphocyte responses were measured by tetramer binding assays. Error bars indicate standard errors of the means (SE).